Study Confirms Coffee May Reduce AFib Risk by 39%: What the DECAF Trial Reveals About Heart Health

For decades, patients with atrial fibrillation were told to avoid coffee at all costs. New research from 2025-2026 is flipping that advice on its head, revealing that moderate coffee consumption may actually protect against irregular heart rhythms.

What Is Atrial Fibrillation and Why Does It Matter?

Atrial fibrillation (AFib) is the most common heart rhythm disorder, affecting more than 10 million adults in the United States alone. According to the American Heart Association, as many as one in three people may experience this condition at some point in their lives.

AFib occurs when the upper chambers of the heart beat irregularly and quickly, disrupting normal blood flow. This can lead to serious complications including blood clots, stroke, and heart failure if left untreated. Common symptoms include:

Fatigue and weakness
Rapid or irregular heartbeat
Chest fluttering or palpitations
Dizziness or lightheadedness
Shortness of breath
Reduced exercise tolerance

The DECAF Trial: A Game-Changer in Heart Rhythm Research

The landmark DECAF trial (Does Eliminating Coffee Avoid Fibrillation?) represents the first randomized clinical trial to directly test the relationship between caffeinated coffee and AFib recurrence. Published in JAMA in November 2025, this study challenges nearly a century of medical wisdom about caffeine and heart health.

Led by researchers at UC San Francisco and the University of Adelaide, the trial enrolled 200 adult participants with persistent atrial fibrillation or atrial flutter who had undergone electrical cardioversion—a procedure that uses controlled electrical shock to restore normal heart rhythm.

Participants were randomly assigned to one of two groups:

Coffee group: Continue drinking at least one cup of caffeinated coffee daily
Abstinence group: Completely avoid all caffeine for six months

The results were striking and unexpected.

Key Findings: 39% Lower Risk with Daily Coffee

After six months of follow-up, researchers found dramatic differences between the two groups:

Outcome	Coffee Group	Abstinence Group	Risk Reduction
AFib/Flutter Recurrence	47%	64%	39% lower hazard
Hospitalization Events	10	15	Numerically lower

The study reported a hazard ratio of 0.61 (95% CI, 0.42-0.89; P=0.01), meaning coffee drinkers had a statistically significant 39% lower risk of AFib recurrence compared to those who abstained from caffeine entirely.

First author Christopher X. Wong, PhD, described the findings as "astounding," noting that doctors have consistently recommended minimizing coffee intake for AFib patients—despite this trial suggesting coffee may actually be protective.

Why Might Coffee Help Rather Than Harm?

Several mechanisms may explain coffee's unexpected cardioprotective effects:

1. Adenosine Receptor Blockade

Caffeine blocks adenosine receptors in the heart, which may mitigate adenosine-induced shortening of atrial action potential duration and refractoriness. This could help maintain stable heart rhythms.

2. Anti-Inflammatory Properties

Coffee contains hundreds of phytochemicals beyond caffeine, including chlorogenic acids and other polyphenols with documented anti-inflammatory effects. Chronic inflammation is a known contributor to AFib development and progression.

3. Blood Pressure Reduction

As a diuretic, caffeine may help reduce blood pressure, which in turn could lessen AFib risk. Senior author Dr. Gregory M. Marcus from UCSF Health noted this potential mechanism in his explanation of the findings.

4. Increased Physical Activity

Recent randomized trials have linked coffee intake to increased physical activity levels. Since regular exercise is known to reduce AFib risk, this behavioral effect may contribute to the observed benefits.

5. Replacement of Less Healthy Beverages

Researchers hypothesized that coffee drinkers may have naturally replaced sugary sodas and other less healthy drinks with coffee, potentially improving overall metabolic health.

Understanding the Study Limitations

While the DECAF trial provides compelling evidence, several important limitations should be noted:

Sample Size: With 200 participants, this was a modest-sized trial. Larger studies are needed to confirm these findings across diverse populations.

Study Design: The trial was not blinded—both physicians and participants knew which group they were in. This could introduce detection and reporting bias, particularly since AFib recurrence was identified through routine clinical care rather than continuous rhythm monitoring.

Adherence Issues: Only 69% of participants in the control group fully adhered to the caffeine avoidance protocol. This incomplete adherence may have led to an underestimation of the true difference between groups.

Specific Population: The study focused on patients with persistent AFib after cardioversion. Results may not apply to those with paroxysmal AFib or individuals without a history of the condition.

Moderate Consumption Only: Participants consumed approximately one cup of coffee per day (about 7 cups per week). These findings do not extend to high-dose caffeine intake or energy drinks.

What Doctors Are Saying

Medical experts emphasize that while the DECAF trial is promising, patients should consult their cardiologists before making changes to their caffeine habits.

Dr. Nicholas Skipitaris, regional director for Cardiac Electrophysiology at Northwell Health, noted: "If you're a chronic coffee drinker, your body may simply get used to the caffeine. It doesn't have the same stimulant effect when consumed consistently."

Dr. Alexa Mieses Malchuk from Geisinger Health added: "Caffeine in moderation is fine for most people. One cup of coffee is not likely to impact your heart rhythm negatively. However, if you notice coffee having an impact on you personally, that may be a sign you shouldn't drink as much caffeine."

Practical Takeaways for AFib Patients

Based on the DECAF trial and expert commentary, here are key considerations:

Don't Panic About Your Morning Coffee: If you have AFib and enjoy moderate coffee consumption (1 cup daily), this research suggests it's likely safe and may even be beneficial.
Individual Responses Vary: Some people may still experience AFib symptoms triggered by caffeine. Monitor your personal response and adjust accordingly.
Quality Over Quantity: The study focused on naturally occurring caffeine from coffee, not high-dose supplements or energy drinks. Stick to moderate amounts.
Continue Your Treatment Plan: About half of study participants were taking antiarrhythmic medications throughout the trial. Coffee should complement, not replace, prescribed treatments.
Talk to Your Doctor: Before making any changes to your caffeine consumption, discuss this research with your cardiologist who understands your specific health profile.

The Bigger Picture: Shifting Medical Paradigms

The DECAF trial exemplifies how medical understanding evolves through rigorous scientific inquiry. What was once considered common wisdom—that caffeine triggers AFib—has been challenged by high-quality evidence.

Previous observational studies had already suggested either neutral or beneficial associations between coffee intake and AFib risk, but the lack of randomized trial data left clinicians uncertain about what to recommend to patients.

Dr. Marcus emphasized in a statement: "It is reasonable for people with AFib who enjoy coffee to try caffeinated drinks. We're seeing evidence that coffee may not worsen their symptoms."

Future Research Directions

The DECAF trial opens several avenues for future investigation:

Larger, multi-center trials to confirm findings across diverse populations
Studies examining different types of caffeinated beverages (tea, energy drinks)
Research into optimal dosage and timing of coffee consumption
Investigation of specific coffee compounds beyond caffeine that may contribute to cardioprotection
Long-term outcome studies extending beyond the six-month follow-up period

Bottom Line

The DECAF trial represents a significant shift in understanding the relationship between coffee and atrial fibrillation. While more research is needed, current evidence suggests that moderate coffee consumption—one cup per day—may be safe and potentially protective for patients with persistent AFib following cardioversion.

For millions of coffee lovers living with heart rhythm disorders, this research offers both practical guidance and renewed hope. The simple daily ritual of enjoying a cup of coffee may contribute meaningfully to maintaining normal heart rhythm.

As always, individual health decisions should be made in consultation with qualified healthcare providers who can assess your unique circumstances and guide personalized recommendations.

References

Wong CX, Cheung CC, Montenegro G, et al. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial. JAMA. 2025;DOI: 10.1001/jama.2025.21056. https://jamanetwork.com/journals/jama/article-abstract/2841253
Miller K. Scientists Say This Popular Sip May Reduce Your Risk of Atrial Fibrillation. Prevention. March 24, 2026. https://www.prevention.com/food-nutrition/a70832180/coffee-safe-atrial-fibrillation-study/
Dutta SS. Daily coffee intake linked to fewer atrial fibrillation relapses. News-Medical. January 30, 2026. https://www.news-medical.net/news/20260130/Daily-coffee-intake-linked-to-fewer-atrial-fibrillation-relapses.aspx
University of California - San Francisco. Surprising heart study finds daily coffee may cut AFib risk by 39%. ScienceDaily. November 10, 2025. https://www.sciencedaily.com/releases/2025/11/251110021046.htm

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making changes to your diet, lifestyle, or treatment plan. If you experience symptoms of atrial fibrillation or other heart conditions, seek immediate medical attention.